

Notice of Allowability

Application No.

10/017,759

Examiner

Satya B Sastri

Applicant(s)

SHIH ET AL.

Art Unit

1713



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to January 23, 2004.
2. ☒ The allowed claim(s) is/are 7-13 and 49.
3. ☒ The drawings filed on 2/14/01 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

Art Unit: 1713

DETAILED ACTION

1. This office action is in response to the amendment filed on January 23, 2004. With the cancellation of *claims 1-6, 18-20 and 18-48, claims 7-17, 49* are now pending in the application. In view of the amendment, objection to *claims 7-17* as being dependent on a rejected claim is moot.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. John D. Carpenter on February 12, 2004.

3. The application has been amended as follows:

Cancel claims 14-17 as the subject matter in the claims is redundant in the amended *claims 8-13*.

The application is also amended to accommodate changes in claim numbers as follows:

- In line 1 of original *claim 8* (final claim 2), change "claim 7" to "claim 1".
- In line 1 of original *claim 9* (final claim 3), change "claim 7" to "claim 1".

Art Unit: 1713

- In line 1 of original *claim 10* (final claim 4), change “claim 7” to “claim 1”.
- In line 1 of original *claim 11* (final claim 5), change “claim 7” to “claim 1”.
- In line 1 of original *claim 12* (final claim 6), change “claim 11” to “claim 5”.
- In line 1 of original *claim 13* (final claim 7), change “claim 7” to “claim 1”.

Allowable Subject Matter

4. *Claims 7-13, 49* are allowed.

5. The following is an examiner’s statement of reasons for allowance:

The present claims are allowable over the closest reference: Baumstark et al. (US 5,774,540).

The present claims are in regard to a composition comprising an acrylic copolymer formed from a plurality of monomers consisting essentially of about 5 to 90% butyl acrylate, about 90% to 5% methyl methacrylate, about 1 to 5% hydroxypropyl acrylate, about 0.1 to 0.5% tetraethylene glycol diacrylate, about 0.1 to 2% methacrylic acid, and about 0.5 to 2% 3-allyloxy-2-hydroxypropylaminoethylethylene urea; a particulate filler and a mordant (*claim 7*).

The disclosure of Baumstark et al. is in regard to an aqueous polymer emulsion comprising a copolymer of hard monomers, soft monomers, and nitrogen-containing adhesion-promoting monomers. The main part of the monomer composition comprising hard and soft monomers accounts for more than 50% by weight, based on the monomer composition. The monomers may be selected exclusively from the following monomers : n-butyl acrylate, 2-

Art Unit: 1713

ethylhexyl acrylate, ethyl acrylate, methyl methacrylate, n-butyl methacrylate, styrene, acrylic acid, methacrylic acid, hydroxyl propylacrylate etc. Water-soluble monomers such as acrylic and methacrylic acid may be present in an amount of from 0.1 to 5%, by weight (column 5, lines 30-37). Crosslinking agents such as alkylene glycol diacrylates and dimethacrylates may be used in an amount of 0.01 to 5% by weight. The disclosure further includes that the monomer compositions may include from 0.5 to 5% by weight, of monomers which do not affect crosslinking until during film formation. Examples of monomers suitable for post crosslinking include hydroxyethyl and hydroxypropyl acrylate and methacrylate are also suitable for post crosslinking. The monomer composition further includes as adhesion promoting monomers, monomers having at least one amino, ureido or N-heterocyclic group. Typical examples of polymerizable ureido monomers disclosed include N-(3allyloxy2-hydroxypropyl) aminoethyleneethylurea, N-(methacrylamidoethyl)ethyleneurea etc. The ureido monomer is polymerized in an amount from 0.1 to 10% by weight, based on the total amount of monomers to be polymerized. The present invention relates to compositions comprising **copolymers consisting essentially of the disclosed monomers in the claimed ranges, a particulate filler and a mordant**. Prior art compositions do not teach or suggest the specific additives or include the specific monomer composition containing triethylene glycol diacrylate and a ureido functional monomer.

Therefore, the instantly claimed invention is deemed allowable over the closest prior art of record as per said art neither anticipating nor rendering obvious the instantly claimed one-component self-adhesive resin based on vinyl polymers in an aqueous medium and a system comprising the adhesive.

Art Unit: 1713

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Satya Sastri at (571) 272-1112.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu can be reached at (571) 272-1114.

Any inquiry of a general nature or relating to the status of this application should be directed to the group receptionist at (703) 308-0661.



SATYA SASTRI

February 12, 2004



DAVID W. WU
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1700